Refractory Angina Market expected to rise, Bristol-Myers Squibb, Aptevo Therapeutics, Novartis Pharmaceuticals, expected to drive market

May 30 11:11 2023
Refractory Angina Market expected to rise, Bristol-Myers Squibb, Aptevo Therapeutics, Novartis Pharmaceuticals, expected to drive market
Refractory Angina Market
DelveInsight’s “Refractory Angina Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Refractory Angina, historical and forecasted epidemiology as well as the Refractory Angina market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Refractory Angina market growth is driven by factors like increase in the prevalence of Refractory Angina, investments in research and development, entry of emerging therapies during the study period 2019-2032.

The Refractory Angina market report also offers comprehensive insights into the Refractory Angina market size, share, Refractory Angina epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Refractory Angina market size growth forward. 

Some of the key highlights from the Refractory Angina Market Insights Report:

  • Several key pharmaceutical companies, including Bristol-Myers Squibb, Aptevo Therapeutics, Novartis Pharmaceuticals, and others, are developing novel products to improve the Myelodysplastic Syndrome treatment outlook. 
  • The total Refractory Angina market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major market.
  • As per DelveInsight analysis, the Refractory Angina market is anticipated to witness growth at a considerable CAGR
  • There are approx. 3+ key companies which are developing the therapies for Refractory Angina. The companies which have their Refractory Angina drug candidates in the most advanced stage, i.e. phase II include, Imbria pharmaceticals.

Strategise your business goals by understanding market dynamics @ Refractory Angina Market Landscape

Refractory Angina Overview 

Refractory Angina is conventionally defined as a chronic condition (≥3 months in duration) characterised by angina in the setting of coronary artery disease (CAD), which cannot be controlled by a combination of optimal medical therapy, angioplasty or bypass surgery, and where reversible myocardial ischaemia has been clinically established to be the cause of the symptoms. There is a sensation of pressure or pain in the chest that is the result of insufficient blood flow to the heart muscle and in which treatment with medication and heart surgery is either insufficient or no longer effective. Patients have reproducible lifestyle-limiting symptoms of chest pain, shortness of breath, and easy fatigability. These symptoms are often due to totally occluded coronary arteries or diffuse coronary atherosclerosis that makes revascularization problematic.

Do you know the treatment paradigms for different countries? Download our Refractory Angina Market Sample Report

Refractory Angina Epidemiology Segmentation 

DelveInsight’s Refractory Angina market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Refractory Angina historical patient pools and forecasted Refractory Angina patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Refractory Angina Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

  • Refractory Angina Prevalence 
  • Age-Specific Refractory Angina Prevalence 
  • Gender-Specific Refractory Angina Prevalence 
  • Diagnosed and Treatable Cases of Refractory Angina

Visit for more @ Refractory Angina Epidemiological Insights

Refractory Angina Treatment Market 

The Refractory Angina market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Refractory Angina market trends by analyzing the impact of current Refractory Angina therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Refractory Angina market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Refractory Angina market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Refractory Angina market in 7MM is expected to witness a major change in the study period 2019-2032.

Key Refractory Angina Emerging Therapies and Key Companies:

  • XC001: XyloCor Therapeutics
  • IMB-101: Imbria pharmaceticals

Refractory Angina Emerging Drugs

XC001: XyloCor Therapeutics

XC001 is an investigational gene therapy for the treatment of patients with refractory angina with no treatment options. Patients who have exhausted pharmacologic options and are not eligible for PCI or coronary artery bypass grafts become sedentary because of their symptoms and this can exacerbate comorbidities causing rapid deterioration of their health status and results in a poor quality of life because of the associated chest pain caused by the ischemia when even moderate physical exertion occurs. XC001 is designed to stimulate the formation of new coronary blood vessels to serve areas of the heart that are not receiving adequate blood supply. This treatment strategy is based on both pre-clinical and clinical evidence and should enable the patients to become less limited in their daily activities because of debilitating chest pain. An Investigational New Drug (IND) application for XC001 is open with the FDA. XyloCor commenced this Phase 1/2 trial in refractory angina in early 2020.

IMB-101: Imbria pharmaceticals

IMB-101 is a novel, investigational cardiac mitotrope in development for the treatment of cardiovascular disease. As a partial fatty acid oxidation (pFOX) inhibitor, IMB-101 is designed to shift myocardial substrate utilization in favor of glucose oxidation to generate more ATP per unit of oxygen consumed thereby increasing myocardial metabolic efficiency. Currently, it is in phase II stage of development to treat refractory angina.

For more information, visit Refractory Angina Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Refractory Angina Market Report:

  • 11 Years Forecast
  • 7MM Coverage 
  • Descriptive overview of Refractory Angina, causes, signs and symptoms, diagnosis, treatment
  • Comprehensive insight into Refractory Angina epidemiology in the 7MM
  • Refractory Angina marketed and emerging therapies 
  • Refractory Angina companies
  • Refractory Angina market drivers and barriers 

Key Questions Answered in the Refractory Angina Market Report 2032:

  • What was the Refractory Angina market share distribution in 2019, and how would it appear in 2032?
  • What is the total Refractory Angina market size and the market size by therapy across the 7MM for the study period (2019-32)?
  • What are the important findings from 7MM, and which country will have the greatest Refractory Angina market size from 2019-32?
  • During the study period (2019-2032), at what CAGR is the Refractory Angina market projected to expand at 7MM?

Table of Contents:

1 Refractory Angina Market Key Comprehensive Insights 

2 Refractory Angina Market Report Introduction

3 Competitive Intelligence Analysis for Refractory Angina

4 Refractory Angina Market Analysis Overview at a Glance

5 Executive Summary of Refractory Angina

6 Refractory Angina Epidemiology and Market Methodology

7 Refractory Angina Epidemiology and Patient Population

8 Refractory Angina Patient Journey

9 Refractory Angina Treatment Algorithm, Refractory Angina Current Treatment, and Medical Practices

10 Key Endpoints in Refractory Angina Clinical Trials

11 Refractory Angina Marketed Therapies 

12 Refractory Angina Emerging Therapies

13 Refractory Angina: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Refractory Angina

16 Refractory Angina Market Key Opinion Leaders Reviews

18 Refractory Angina Market Drivers

19 Refractory Angina Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Refractory Angina Epidemiology 2032

DelveInsight’s “Refractory Angina – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Refractory Angina epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Refractory Angina Pipeline 2023

“Refractory Angina Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Refractory Angina market. A detailed picture of the Refractory Angina pipeline landscape is provided, which includes the disease overview and Refractory Angina treatment guidelines. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States

view more articles

About Article Author